During the last session, Abeona Therapeutics Inc (NASDAQ:ABEO)’s traded shares were 0.43 million, with the beta value of the company hitting 1.52. At the end of the trading day, the stock’s price was $4.42, reflecting an intraday loss of -1.12% or -$0.05. The 52-week high for the ABEO share is $9.01, that puts it down -103.85 from that peak though still a striking 34.84% gain since the share price plummeted to a 52-week low of $2.88. The company’s market capitalization is $181.04M, and the average intraday trading volume over the past 10 days was 0.32 million shares, and the average trade volume was 459.79K shares over the past three months.
Abeona Therapeutics Inc (ABEO) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. ABEO has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.36.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Abeona Therapeutics Inc (NASDAQ:ABEO) trade information
Abeona Therapeutics Inc (ABEO) registered a -1.12% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.12% in intraday trading to $4.42, hitting a weekly high. The stock’s 5-day price performance is -5.96%, and it has moved by -14.84% in 30 days. Based on these gigs, the overall price performance for the year is 47.33%. The short interest in Abeona Therapeutics Inc (NASDAQ:ABEO) is 3.08 million shares and it means that shorts have 7.17 day(s) to cover.
The consensus price target of analysts on Wall Street is $6, which implies an increase of 26.33% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $6 respectively. As a result, ABEO is trading at a discount of -35.75% off the target high and -35.75% off the low.
Abeona Therapeutics Inc (ABEO) estimates and forecasts
Statistics show that Abeona Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Abeona Therapeutics Inc (ABEO) shares have gone down -16.29% during the last six months, with a year-to-date growth rate less than the industry average at 11.71% against 16.60. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 60.90% this quarter and then jump 25.00% in the quarter after that. In the rating firms’ projections, revenue will decrease -92.90% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 80k as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 80k by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 38.92%. While earnings are projected to return 31.82% in 2024.
ABEO Dividends
Abeona Therapeutics Inc is due to release its next quarterly earnings 2024-Aug-09. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Abeona Therapeutics Inc (NASDAQ:ABEO)’s Major holders
Abeona Therapeutics Inc insiders own 3.24% of total outstanding shares while institutional holders control 61.75%, with the float percentage being 63.81%.
Also, the Mutual Funds coming in first place with the largest holdings of Abeona Therapeutics Inc (ABEO) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . Data provided on Mar 31, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 739.76 shares. This amounts to just over 1.81 percent of the company’s overall shares, with a $3.27 million market value. The same data shows that the other fund manager holds slightly less at 319.14, or about 0.78% of the stock, which is worth about $1.41 million.
